Diovan (valsartan) 160 mg, 90 tablets, Rx only, Manufactured by: Patheon Manufacturing Services LLC, Greenville, NC 27834, Distributed by: Novartis Pharmaceutical Corp, East Hanover, NJ 07936, NDC 0078-0359-34

Failed Dissolution Specifications

Recall #: D-0746-2026
Initiated: August 4, 2026

Compiled from official public sources by the publisher. · Updated September 2026

Novartis Pharmaceuticals Corporation recalled Diovan (valsartan) 160 mg, 90 tablets, Rx only, Manufactured by: Patheon Manufacturing Se… - a moderate-severity action.

Diovan (valsartan) 160 mg, 90 tablets, Rx only, Manufactured by: Patheon Manufacturing Se… was recalled by Novartis Pharmaceuticals Corporation in August 19, 2026. Reason: Failed Dissolution Specifications. Check the official notice for the remedy. Verify recall #D-0746-2026 with the FDA Drug before acting.

The recall

Novartis Pharmaceuticals Corporation issued this moderate-severity FDA Drug recall-Failed Dissolution Specifications.

Moderate
severity level: Class II
classification: August 19, 2026
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-0746-2026 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This FDA Drug action (record #D-0746-2026) was formally reported on August 19, 2026, with the manufacturer initiating the action on August 4, 2026. It is classified under Moderate severity (Class II), with a current status of Ongoing. Novartis Pharmaceuticals Corporation is listed as the recalling firm, operating out of East Hanover, NJ. The number of affected units is not disclosed in the agency filing, which is common for drug and food recalls where lot-level tracking supersedes unit counts.

The documented reason for this recall is: Failed Dissolution Specifications Distribution data in the federal record shows the product reached: US Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 6 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Where this agency-classified recall sits among FDA Class I/II/III notices

Of 88,244 recalls with an agency hazard classification, 19,068 are high severity, 64,652 moderate, and 4,524 low. A further 16,179 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified moderate severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Product description

Diovan (valsartan) 160 mg, 90 tablets, Rx only, Manufactured by: Patheon Manufacturing Services LLC, Greenville, NC 27834, Distributed by: Novartis Pharmaceutical Corp, East Hanover, NJ 07936, NDC 0078-0359-34

Reason for recall

Failed Dissolution Specifications

Recall Profile

Structured summary of the FDA Drug recall record
Attribute	Value
Agency	U.S. Food and Drug Administration
Severity class	Moderate (Class II)
Status	Ongoing
Recall number	D-0746-2026
Date reported	August 19, 2026
Date initiated	August 4, 2026
Recalling firm	Novartis Pharmaceuticals Corporation
Firm location	East Hanover, NJ
Affected scope	Not disclosed
Distribution	US Nationwide

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

Check the recall number (D-0746-2026) and product description against the item you own. Search the archive
Confirm the current status with FDA Drug before acting, recall details can be updated.
Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled? ▼

Why was this product recalled? ▼

Failed Dissolution Specifications

Which agency issued this recall? ▼

This recall was issued by the FDA Drug on August 19, 2026. Severity: Moderate. Recall number: D-0746-2026.

Where was the recalled product distributed? ▼

Distribution: US Nationwide.

Should I stop using a recalled medication or medical device? ▼

Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nationwide recalls with similar severity or category timing

Drug and device notices outside this firm and state, matched by severity timing and product category.

Similar severity · nearest report date

Same archive severity grade (Moderate), closest by report date among other firms and states.

SEMAGLUTIDE 12.5MG (2.5MG/mL), 5 mL Steri… 2026-08-19 SEMAGLUTIDE 2.25MG (0.9 mg/mL), 2.5 mL St… 2026-08-19 SEMAGLUTIDE 6.75mg (4.5 mg/mL), 1.5 mL St… 2026-08-19 SEMAGLUTIDE 4.5mg (0.9 mg/mL), 5 mL Steri… 2026-08-19

Similar Drugs & Medications · nearest report date

Same product category, closest by report date among other firms and states (deduped against the severity set).

Cefazolin in Dextrose, Injection, USP, 2g… 2026-08-19 SEMAGLUTIDE 9mg (4.5 mg/mL), 2 mL Sterile… 2026-08-19 SEMAGLUTIDE 0.9mg (0.9 mg/mL), 1 mL Steri… 2026-08-19 SEMAGLUTIDE 2.5mg (1mg/mL), Glycine 12.5 … 2026-08-19

Compare this recall with Kian Pee Wan Capsules, 30-count bottles → · All Drugs & Medications recalls

This recall: FDA Drug, reported August 19, 2026. Severity classes follow each agency's own taxonomy; related-recall context is computed across the full archive.

Methodology · Corrections · Archive as of August 2026